A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail GT

Inclusion Criteria:

• Subject is a male or non-pregnant female age 18 years or older at the time ofsurgery;

• Subject is willing and able to give written informed consent and comply with therequirements of this Clinical Investigation Plan;

• Subject is intended to be treated with the Femoral Nail GT of the T2 Alpha FemurAntegrade GT/PF Nailing System in accordance with the following legally cleared/approved Indications for Use:

Indications for Use approved Outside of Europe include:

• Fixation of subtrochanteric, intertrochanteric, ipsilateral neck/shaft, comminutedproximal femoral shaft fractures

• Femoral fixation required as a result of pathological disease

• Temporary stabilization of fractures of the femoral shaft ranging from the femoralneck to the supracondylar regions of the femur

• Open and closed femoral fractures

• Pseudoarthrosis and correction osteotomy

• Pathologic fractures, impending pathologic fractures and tumor resections

• Ipsilateral femur fractures

• Fractures proximal to a total knee arthroplasty

• Nonunions and malunions

• Fractures involving osteopenic and osteoporotic bone

Exclusion Criteria:

• Subject is currently enrolled in or plans to enroll in any concurrent drug and/ordevice clinical investigation that, in the opinion of the Investigator, may confoundresults;

• Per the Investigator, the subject is in poor general health or undergoing anyconcurrent disease that would place the subject in excessive risk to surgery (i.e.significant circulatory problems, cardiac disease).